1-异丙基咪唑i二n-2-亚胺 | 766449-90-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑啉类
• 中文名称: 1-异丙基咪唑i二n-2-亚胺
• 英文名称: 1-isopropyl-4,5-dihydro-1H-imidazol-2-ylamine
• 英文别名: 1-Propan-2-yl-4,5-dihydroimidazol-2-amine
• CAS: 766449-90-5
• 化学式: C₆H₁₃N₃
• 分子量: 127.189
• InChiKey: MPDMEQLGLCDAFF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  41.6
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-异丙基咪唑i二n-2-亚胺 在 氨 、 三乙胺 、 mercury dichloride 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 72.5h， 生成 N-(3,4-dichlorophenyl)-N'-(1-isopropyl-4,5-dihydro-1H-imidazol-2-yl)guanidine hydrochloride
  参考文献：
  名称：

  Antimalarial Activities of New Guanidylimidazole and Guanidylimidazoline Derivatives

  摘要：

  A series of new guanidylimidazole derivatives was prepared and evaluated in mice and Rhesus monkeys infected with malarial sporozoites. The majority of the new compounds showed poor metabolic stability and weak in vitro activities in three clones of Plasmodium falciparum. Compounds 8a, 8h, 9a, 16a, and 16e cured the mice infected with sporozoites of P. berghei at 160 and 320 mg/kg/day x 3 po. Compounds 8a showed better causal prophylactic activity than primaquine, tafenoquine, and Malarone in the Rhesus test. In the radical curative test, 8a cured one monkey and delayed relapse of another for 74 days at 30 mg/kg/day x 7 by im. By oral dosing, 8a delayed relapse 81 days for one and 32 days for other vs 11-12 days for control monkeys treated with 10 mg/kg of chloroquine by po alone. Compound 8h, which showed superior activity to 8a in mouse test, delayed the relapse of treated monkeys for 21-26 days at 30 mg/kg/day x 7 by oral.

  DOI：

  10.1021/jm200503s
• 作为产物：
  描述：

  1-Isopropyl-2-methylmercapto-Δ²-imidazolin 在 ammonium hydroxide 作用下， 生成 1-异丙基咪唑i二n-2-亚胺
  参考文献：
  名称：

  Antimalarial Activities of New Guanidylimidazole and Guanidylimidazoline Derivatives

  摘要：

  A series of new guanidylimidazole derivatives was prepared and evaluated in mice and Rhesus monkeys infected with malarial sporozoites. The majority of the new compounds showed poor metabolic stability and weak in vitro activities in three clones of Plasmodium falciparum. Compounds 8a, 8h, 9a, 16a, and 16e cured the mice infected with sporozoites of P. berghei at 160 and 320 mg/kg/day x 3 po. Compounds 8a showed better causal prophylactic activity than primaquine, tafenoquine, and Malarone in the Rhesus test. In the radical curative test, 8a cured one monkey and delayed relapse of another for 74 days at 30 mg/kg/day x 7 by im. By oral dosing, 8a delayed relapse 81 days for one and 32 days for other vs 11-12 days for control monkeys treated with 10 mg/kg of chloroquine by po alone. Compound 8h, which showed superior activity to 8a in mouse test, delayed the relapse of treated monkeys for 21-26 days at 30 mg/kg/day x 7 by oral.

  DOI：

  10.1021/jm200503s

文献信息

• Bicyclic heterocycles as HIV-integrase inhibitors
  申请人：Banville Jacques

  公开号：US20070049606A1

  公开（公告）日：2007-03-01

  The invention encompasses a series cyclic bicyclic heterocyclic compounds of Formula I which are inhibitors of HIV integrase and prevent viral integration into human DNA. This action makes the compounds useful for treating HIV infection and AIDS. The invention also encompasses pharmaceutical compositions and methods for treating those infected with HIV.

  本发明涵盖了一系列公式I的环状双环杂环化合物，它们是HIV整合酶的抑制剂，可以防止病毒整合到人类DNA中。这种作用使得这些化合物在治疗HIV感染和艾滋病方面非常有用。本发明还涵盖了用于治疗HIV感染者的药物组合物和方法。
• Guanidinium delivery carriers
  申请人：Zhao Gang

  公开号：US20070078094A1

  公开（公告）日：2007-04-05

  Disclosed herein are transmembrane transporter compounds containing guanidinium groups. Also disclosed herein are methods for transporting a biologically active moiety across a biological membrane using the transmembrane transporter compounds. Particularly, this invention provides a method for the delivery of a biologically active moiety across the biological membranes of such membranes as endothelial tissues.

  本文披露了含有胍基团的跨膜转运体化合物。本文还披露了使用跨膜转运体化合物将生物活性基团跨越生物膜的方法。特别地，本发明提供了一种将生物活性基团传递到内皮组织等生物膜的方法。
• PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT
  申请人：Gilead Sciences, Inc.

  公开号：US20140154240A1

  公开（公告）日：2014-06-05

  The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.

  本发明提供了I式或II式的化合物： 或其药学上可接受的盐或酯，如本文所述。这些化合物及其组合物对治疗Pneumovirinae病毒感染有用。所提供的化合物、组合物和方法特别适用于治疗人类呼吸道合胞病毒感染。
• BICYCLIC HETEROCYCLES AS HIV INTEGRASE INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：EP1919921B1

  公开（公告）日：2012-06-27
• PEPTIDE NUCLEIC ACID BASED GUANIDINIUM COMPOUNDS
  申请人：Zhao Gang

  公开号：US20100160239A1

  公开（公告）日：2010-06-24

  Disclosed herein are transmembrane transporter compounds containing guanidinium groups to enhance transport across biomembranes. Therapeutic and other biologically active moieties may be attached to the compounds. The transmembrane transporter compounds may include peptide nucleic acid monomer units.